The "Molecular Switch Targeting Therapies Market Landscape, Innovation Pipeline and Commercial Impact 2026" report has been added to ResearchAndMarkets.com's offering. The report is designed to give ...

In a new study, researchers have determined that a protein called NF-kB c-Rel can intensify the symptoms of psoriasis when activated by signals from the body's immune system. Understanding how 'c-Rel' ...

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with ...

This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.

Your body might be sending you hints about your health.

The FDA has granted Breakthrough Therapy designation for litifilimab for the treatment of cutaneous lupus erythematosus, a chronic autoimmune skin disease.

Treatment with apremilast led to improvements in genital psoriasis signs, symptoms, and patient QOL through 32 weeks.

Linda Stein Gold, MD, shares insights on new therapeutic options for patients with various psoriasis subtypes and psoriatic arthritis.

Systemic lupus erythematosus commonly presents as a rash. The rashes are caused by inflammation from the immune system fighting the body. Systemic lupus erythematosus, more commonly known as lupus, ...

Modern disease is complex and individual. Biopharma offers a biological approach to more precise, effective treatment ...

This winter has been brrrutal. As if the freezing temperatures, slippery sidewalks, high heating bills, dry, flaky skin, ...